BMS Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -227 Part 1a Study for 1L Non-Small Cell Lung Cancer

 BMS Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -227 Part 1a Study for 1L Non-Small Cell Lung Cancer

BMS Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -227 Part 1a Study for 1L Non-Small Cell Lung Cancer

Shots:

  • The P-III CheckMate -227 Part 1a study involves assessing of Opdivo + Yervoy vs platinum-doublet CT in patients with 1L advanced NSCLC across non-squamous and squamous tumor expressing PD-L1 ≥1%
  • The P-III Checkmate -227 Part 1a study resulted in meeting its 1EPs of overall survival. BMS also announced that Part 2 of CheckMate -227 study evaluating Opdivo plus CT, did not meet its 1EPs of OS in patients with 1L non-sq NSCLC regardless of PD-L1 status
  • Opdivo is a PD-1 immune checkpoint inhibitor harnessing the body’s own immune system to restore anti-tumor immune response, indicated as monothx. or in combination with Yervoy to treat multiple cancer

Click here, Click here to­ read full press release/ article | Ref: BMS | Image: Record-Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post